MONTPELLIER, France–(BUSINESS WIRE)–Regulatory Information:
Sensorion (FR0012596468 “ ALSEN) a pioneering clinical-stage biotechnology firm which specializes within the improvement of novel therapies to revive, deal with and forestall inside the discipline of listening to loss problems, at the moment declares the appointment of Ms Laurene Danon as Chief Monetary Officer.
Laurene brings to Sensorion greater than 15 years of expertise in funding banking and worldwide fairness capital markets. A graduate of HEC, she started her profession in London with the funding financial institution J.P. Morgan, in company finance advisory, earlier than specializing in fairness capital markets at J.P. Morgan and later at Jefferies Worldwide. Previous to becoming a member of Sensorion, she based the strategic advisory agency Concorde Advisory, the place she supported and managed the execution of strategic company finance tasks for her purchasers. In whole, Laurene has led executions for 70 transactions totaling over $35 billion raised.
Laurene was well-known to the Sensorion group, having suggested the corporate on latest capital will increase.
Laurene Danon, Chief Monetary Officer of Sensorion, mentioned: “I’m delighted to have the chance to hitch Sensorion at a pivotal second in its historical past, marked by a robust acceleration of its applications, significantly in gene remedy. These applications are at the moment receiving sturdy assist from the medical group, sufferers and their households, in addition to buyers. I’m decided to work with the entire group at Sensorion to additional develop extremely revolutionary therapies for listening to problems, a big world unmet medical want.”
Nawal Ouzren, Chief Govt Officer of Sensorion, mentioned: I’m excited to welcome Laurene whose appointment represents good news for Sensorion and comes at a time of great alternative and development for Sensorion. She brings a wealth of data that can play a paramount position in supporting advances in Sensorion’s pipeline. Along with her confirmed experience of worldwide capital markets, she shall be an excellent addition to our administration’s group and can immensely contribute in Sensorion’s mission to deliver doubtlessly life-transformative options to folks dwelling with listening to problems.
About Sensorion
Sensorion is a pioneering clinical-stage biotech firm, which specializes within the improvement of novel therapies to revive, deal with, and forestall listening to loss problems, a big world unmet medical want. Sensorion has constructed a novel R&D expertise platform to develop its understanding of the pathophysiology and etiology of interior ear associated illnesses, enabling it to pick out one of the best targets and mechanisms of motion for drug candidates.
It has two gene remedy applications geared toward correcting hereditary monogenic types of deafness, developed within the framework of its broad strategic collaboration centered on the genetics of listening to with the Institut Pasteur. SENS-501 (OTOF-GT) at the moment being developed in a Part 1/2 scientific trial, targets deafness brought on by mutations of the gene encoding for otoferlin and GJB2-GT targets listening to loss associated to mutations in GJB2 gene to doubtlessly deal with vital listening to loss segments in adults and kids. The Firm can be engaged on the identification of biomarkers to enhance prognosis of those underserved diseases.
Sensorion’s portfolio additionally includes clinical-stage small molecule applications for the therapy and prevention of listening to loss problems. Sensorion’s clinical-stage portfolio consists of one Part 2 product: SENS-401 (Arazasetron) progressing in a deliberate Part 2 proof of idea scientific research of SENS-401 in Cisplatin-Induced Ototoxicity (CIO) and, with companion Cochlear Restricted, in a research of SENS-401 in sufferers scheduled for cochlear implantation. A Part 2 research of SENS-401 was additionally accomplished in Sudden Sensorineural Listening to Loss (SSNHL) in January 2022.
www.sensorion.com
Label: SENSORIONISIN: FR0012596468Mnemonic: ALSEN
Disclaimer
This press launch incorporates sure forward-looking statements regarding Sensorion and its enterprise. Such ahead wanting statements are primarily based on assumptions that Sensorion considers to be cheap. Nevertheless, there could be no assurance that such forward-looking statements shall be verified, which statements are topic to quite a few dangers, together with the dangers set forth within the 2023 full yr report revealed on March 14, 2024, and accessible on our web site and to the event of financial situations, monetary markets and the markets during which Sensorion operates. The forward-looking statements contained on this press launch are additionally topic to dangers not but recognized to Sensorion or not at the moment thought of materials by Sensorion. The incidence of all or a part of such dangers may trigger precise outcomes, monetary situations, efficiency or achievements of Sensorion to be materially completely different from such forward-looking statements. This press launch and the knowledge that it incorporates don’t represent a suggestion to promote or subscribe for, or a solicitation of a suggestion to buy or subscribe for, Sensorion shares in any nation. The communication of this press launch in sure nations could represent a violation of native legal guidelines and rules. Any recipient of this press launch should inform oneself of any such native restrictions and comply therewith.
View supply model on businesswire.com: https://www.businesswire.com/information/residence/20240626797971/en/
Investor RelationsNoémie Djokovic, Investor Relations and Communication Associateir.contact@sensorion-pharma.com
Press RelationsUlysse CommunicationBruno Arabian / 00 00(0)6 87 88 47 26barabian@ulysse-communication.comNicolas Entz / 00 33 (0)6 33 67 31 54nentz@ulysse-communication.com
Supply: Sensorion
